SFX by Ex Libris Inc.

Title:	Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
Source:	Journal of Medicinal Chemistry [0022-2623] Sit, S Y yr:1990

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Wierzbicki, Anthony S. "Synthetic statins: more data on newer lipid-lowering agents." Current medical research and opinion 17.1 (2001): 74-77.
description	2.	Balasubramanian, N. "A potent, tissue-selective, synthetic inhibitor of HMG-CoA reductase." Journal of medicinal chemistry 32.9 (1989): 2038-2041.
description	3.	White, C Michael M. "A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin." The Journal of clinical pharmacology 42.9 (2002): 963-70.
description	4.	Haria, M. Drugs 53.2 (1997): 299-336.
description	5.	Moyad, Mark A. "Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part IV--is vitamin E phosphate or another unique type of this vitamin the last chance for these supplements?" Urologic Nursing (2006): 415-418.
description	6.	Thompson, C A A. "Cerivastatin withdrawn from the market." American journal of health-system pharmacy 58.15 (2001): 1685-.
description	7.	Yu, Kuo g. "Synthesis and chemical properties of tetrazole peptide analogs." Journal of organic chemistry 52.10 (1987): 2051-2059.
description	8.	Wang, A. "Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients." European journal of clinical pharmacology 60.12 (2005): 843-8.
description	9.	Stein, E. "Comparison of statins in hypertriglyceridemia." The American journal of cardiology 81.4A (1998): 66-69.
description	10.	Altman, Ryan A. "An Improved Cu-Based Catalyst System for the Reactions of Alcohols with Aryl Halides." Journal of organic chemistry 73.1 (2008): 284-286.
description	11.	Jain, Mukesh K K. "Anti-inflammatory effects of statins: clinical evidence and basic mechanisms." Nature reviews. Drug discovery 4.12: 977-987.
description	12.	Baumann, P. "Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors." Clinical pharmacokinetics 41.5: 444-469.
description	13.	Cushman, P M M. "Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men." New England Journal of Medicine, The 336.14 (1997): 973-9.
description	14.	Shinji, C. "Design and synthesis of phthalimide-type histone deacetylase inhibitors." Bioorganic & medicinal chemistry letters 15.20 (2005): 4427-9.
description	15.	Istvan, E S S. "Structural mechanism for statin inhibition of HMG-CoA reductase." Science 292.5519 (2001): 1160-4.
description	16.	Huang, J. "The impact of dietary changes and dietary supplements on lipid profile." The Canadian journal of cardiology 27.4 (2011): 488-505.
description	17.	Ito, Matthew K E. "Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias - 2005." Pharmacotherapy 26.7 (2006): 939-1010.
description	18.	Poli, A. Drugs 67.Supplement 1 (2007): 3-15.
description	19.	Neuvonen, Pertti J J. "Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance." Clinical pharmacology and therapeutics 80.6 (2006): 565-581.
description	20.	Kosoglou, T. "Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions." Clinical pharmacokinetics 44.5 (2005): 467-94.